{"name":"Deepak K. Sarpal, M.D.","slug":"deepak-k-sarpal-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Anticholinergic Deprescription","genericName":"Anticholinergic Deprescription","slug":"anticholinergic-deprescription","indication":"Reduction of anticholinergic medication burden in patients taking multiple anticholinergic agents","status":"marketed"},{"name":"No Anticholinergic Deprescription","genericName":"No Anticholinergic Deprescription","slug":"no-anticholinergic-deprescription","indication":"Reduction of anticholinergic medication burden in patients at risk for anticholinergic-related adverse effects","status":"marketed"}]}],"pipeline":[{"name":"Anticholinergic Deprescription","genericName":"Anticholinergic Deprescription","slug":"anticholinergic-deprescription","phase":"marketed","mechanism":"Anticholinergic deprescription is a clinical practice of systematically reducing or discontinuing anticholinergic medications to minimize cognitive and physical adverse effects.","indications":["Reduction of anticholinergic medication burden in patients taking multiple anticholinergic agents","Prevention of cognitive decline and delirium in older adults","Reduction of fall risk in elderly patients"],"catalyst":""},{"name":"No Anticholinergic Deprescription","genericName":"No Anticholinergic Deprescription","slug":"no-anticholinergic-deprescription","phase":"marketed","mechanism":"This is a deprescribing strategy that involves the discontinuation or reduction of anticholinergic medications in patients where they are no longer clinically indicated.","indications":["Reduction of anticholinergic medication burden in patients at risk for anticholinergic-related adverse effects"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}